| EP300 Selectively Controls the Enhancer Landscape of MYCN-Amplified Neuroblastoma AD Durbin, T Wang, VK Wimalasena, MW Zimmerman, D Li, NV Dharia, ... Cancer discovery 12 (3), 730-751, 2022 | 90 | 2022 |
| Development and preclinical validation of a novel covalent ubiquitin receptor Rpn13 degrader in multiple myeloma Y Song, PMC Park, L Wu, A Ray, S Picaud, D Li, VK Wimalasena, T Du, ... Leukemia 33 (11), 2685-2694, 2019 | 47 | 2019 |
| Using chemical epigenetics to target cancer VK Wimalasena, T Wang, LH Sigua, AD Durbin, J Qi Molecular cell 78 (6), 1086-1095, 2020 | 46 | 2020 |
| Lysine demethylase 5A Is required for MYC-driven transcription in multiple myeloma H Ohguchi, PMC Park, T Wang, BE Gryder, D Ogiya, K Kurata, X Zhang, ... Blood cancer discovery 2 (4), 370-387, 2021 | 24 | 2021 |
| Colicin E1 opens its hinge to plug TolC SJ Budiardjo, JJ Stevens, AL Calkins, AP Ikujuni, VK Wimalasena, E Firlar, ... Elife 11, e73297, 2022 | 20 | 2022 |
| Development of Dimethylisoxazole-Attached Imidazo[1,2-a]pyridines as Potent and Selective CBP/P300 Inhibitors A Muthengi, VK Wimalasena, HO Yosief, MJ Bikowitz, LH Sigua, T Wang, ... Journal of medicinal chemistry 64 (9), 5787-5801, 2021 | 19 | 2021 |
| Ep300 selectively controls the enhancer landscape of MYCN-amplified neuroblastoma. Cancer Discov. 2022; 12: 730–751. doi: 10.1158/2159-8290 AD Durbin, T Wang, VK Wimalasena, MW Zimmerman, D Li, NV Dharia, ... CD-21-0385.[PMC free article][PubMed][CrossRef][Google Scholar], 0 | 8 | |
| N-Methyl-4-phenylpyridinium Scaffold-Containing Lipophilic Compounds Are Potent Complex I Inhibitors and Selective Dopaminergic Toxins B Lickteig, VK Wimalasena, K Wimalasena ACS chemical neuroscience 10 (6), 2977-2988, 2019 | 6 | 2019 |
| Exploiting polarity and chirality to probe the Hsp90 C-terminus LK Forsberg, RE Davis, VK Wimalasena, BSJ Blagg Bioorganic & medicinal chemistry 26 (12), 3096-3110, 2018 | 6 | 2018 |
| Small molecule target bromo/acetyl proteins and uses thereof J Qi, D Li, VK Wimalasena, P Park US Patent App. 17/617,226, 2022 | 1 | 2022 |
| EP300 controls the oncogenic enhancer landscape of high-risk neuroblastoma AD Durbin, V Wimalasena, MW Zimmerman, L Deyao, ES Frank, P Park, ... CANCER RESEARCH 80 (14), 37-37, 2020 | 1 | 2020 |
| Colicin E1 Fragments Potentiate Antibiotics by Plugging TolC SJ Budiardjo, JJ Deay, AL Calkins, VK Wimalasena, D Montezano, ... bioRxiv, 692251, 2019 | 1 | 2019 |
| TARGETED SMALL MOLECULE BROMO/ACETYL PROTEINS AND THEIR USES J Qi, LI Deyao, VK Wimalasena, P Park | | 2023 |
| EP300 selectively controls the enhancer landscape of high risk neuroblastoma AD Durbin, T Wang, VK Wimalasena, MW Zimmerman, D Li, NV Dharia, ... Cancer Research 81 (13_Supplement), 2318-2318, 2021 | | 2021 |
| Small molecule target bromo/acetyl proteins and uses thereof J Qi, LI Deyao, VK WIMALASENA, P Park | | 2020 |
| Abstract PR11: EP300 controls the oncogenic enhancer landscape of high-risk neuroblastoma AD Durbin, V Wimalasena, MW Zimmerman, L Deyao, ES Frank, P Park, ... Cancer Research 80 (14_Supplement), PR11-PR11, 2020 | | 2020 |
| Determining the Specificity of Designed Peptide that Inhibits Antibiotic Resistance VK Wimalasena, J Budiardjo, CBR Cook, JSG Slusky Biophysical Journal 114 (3), 609a, 2018 | | 2018 |
| 15Lead Contact 30 AD Durbin, T Wang, VK Wimalasena, MW Zimmerman, D Li, NV Dharia, ... | | |
Joanna S.G. SluskyAssociate Professor, University of Kansas在 ku.edu 的电子邮件经过验证
Joanna S.G. SluskyAssociate Professor, University of Kansas在 ku.edu 的电子邮件经过验证
Brian BlaggProfessor of Chemistry and Biochemistry在 nd.edu 的电子邮件经过验证